Pharmacological Targeting of the Actin Cytoskeleton to Drive Endocrinogenesis

Johanna Siehler; Anna Karolina Blöchinger; Heiko Lickert

doi:10.1016/j.tips.2020.04.002

Pharmacological Targeting of the Actin Cytoskeleton to Drive Endocrinogenesis

Trends Pharmacol Sci. 2020 Jun;41(6):384-386. doi: 10.1016/j.tips.2020.04.002. Epub 2020 Apr 24.

Authors

Johanna Siehler¹, Anna Karolina Blöchinger¹, Heiko Lickert²

Affiliations

¹ Institute of Diabetes and Regeneration Research, Helmholtz Zentrum München, 85764 Neuherberg, Germany.
² Institute of Diabetes and Regeneration Research, Helmholtz Zentrum München, 85764 Neuherberg, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany; Chair of β-Cell Biology Technische Universität München, School of Medicine, Klinikum Rechts der Isar, Ismaninger Straße 22, 81675 München, Germany. Electronic address: heiko.lickert@helmholtz-muenchen.de.

PMID: 32340752
DOI: 10.1016/j.tips.2020.04.002

Abstract

In vitro generation of insulin-secreting beta cells from human pluripotent stem cells (hPSCs) opens new avenues for treating and modeling diabetes. Hogrebe and colleaguesestablished a new 2D differentiation protocol where they targeted the cytoskeleton pharmacologically for controlled endocrine induction and generation of hPSC-derived beta cells with improved function.

Keywords: Latrunculin A; actin; beta cells; endocrine progenitors; pancreatic progenitors; stem cells.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Actin Cytoskeleton
Cell Differentiation
Cytoskeleton
Humans
Pancreas
Pluripotent Stem Cells*